Aralez Pharma (ARLZ) reported quarterly earnings results on Tuesday, May-10-2016. The company reported $-0.73 earnings per share for the quarter, missing the analyst consensus estimate by $-0.20. Analysts had a consensus of $-0.53. The company posted revenue of $8.10 million in the period, compared to analysts expectations of $10.08 million. The company’s revenue was up 84.1% compared to the same quarter last year.
Many Wall Street Analysts have commented on Aralez Pharma. Shares were Reiterated by Chardan Capital Markets on Mar 16, 2016 to “Buy” and Lowered the Price Target to $ 10 from a previous price target of $15.50 .